Data could move J&J’s Talvey earlier in myeloma therapy

Pharmaphorum

Johnson Johnson's Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

pharminent June 15, 2026 (Last updated: June 15, 2026)

Pharmaphorum

Johnson Johnson’s Talvey looks set to move second-line in multiple myeloma treatment, based on the results of the MonumenTAL-3 trial at EHA 2026.

Related Stories